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Title 
Prognostic value of serum HE4 levels and Risk of Ovarian Malignancy Algorithm (ROMA) 
scores at the time of ovarian cancer diagnosis. 
Abstract  
Objectives: To assess whether pretreatment serum HE4 levels or ROMA scores at time of 
initial diagnosis are associated with progression-free (PFS) and disease specific survival 
(DSS) in patients with ovarian cancer receiving either primary debulking surgery (PDS) or 
neo-adjuvant chemotherapy (NACT) followed by interval debulking surgery. 
Methods: Survival analysis of 101 cases of invasive ovarian cancer recruited in a previous 
diagnostic accuracy study conducted from 2005-2009 at the University Hospitals KU Leuven, 
Belgium. Serum HE4 (pM) and Risk of Ovarian Malignancy Algorithm (ROMA) scores (%) 
were obtained prior to primary treatment. Dates of death were obtained by record linkage with 
patient hospital files. Progression was evaluated according to RECIST criteria. Adjusted 
hazard ratios (HR) were estimated using multivariable Cox regression. Results: 80 patients 
(79%) with invasive ovarian cancer underwent PDS whereas 21 (21%) received NACT. 
Median DSS was 3.72 years; 95% CI: 3.19-4.07. 52 (51%) patients died of disease, and 74 
(73%) patients had progressive disease during follow-up. On univariable analysis, 
pretreatment HE4 levels and ROMA scores were related to worse prognosis. However, after 
adjustment for classical prognostic variables, HE4 levels (log2-transformed) and ROMA 
scores were unrelated to DSS (HE4: adjusted HR 1.01, 95% CI 0.84-1.21; ROMA: adjusted 
HR per 10% increase 0.96, 95% CI 0.84-1.12) and PFS (HE4: adjusted HR 0.98, 95% CI 
0.84-1.13; ROMA: adjusted HR per 10% increase 0.98, 95% CI 0.88-1.11). 
Conclusions: Pretreatment HE4 levels and ROMA scores are not independent prognostic 
factors for DSS and PFS after multivariable adjustment in patients with ovarian cancer.  
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Introduction 
Ovarian cancer is a leading cause of gynecologic cancer-related death, with an age-adjusted 
mortality rate of 8.1 per 100.000 women per year. It is estimated that 22,240 women would be 
diagnosed with ovarian cancer in 2013 in the United States. Most of them will be confronted 
with advanced stage disease and eventually more than two thirds of patients will die from its 
disease course.1  
Currently physicians widely use the staging system of the International Federation of 
Gynecology and Obstetrics (FIGO) to counsel individual patients regarding their prognosis.2 
Moreover, ovarian cancer is now being regarded as a heterogeneous disease entity with 
different appearances, biological and genetic backgrounds and concomitant clinical features.3 
This causes difficulties in predicting progression-free (PFS) and overall survival (OS) for 
individual patients. Other factors besides FIGO staging have a clear prognostic significance in 
patients with epithelial ovarian cancer. Many of them have already been incorporated into 
different clinical nomograms.4-6 These include age; performance status; American Society of 
Anesthesiologist (ASA) score; tumor grade; histology; FIGO stage; residual tumor volume 
after cytoreductive surgery; serum alkaline phosphatase; serum albumin; hemoglobin level; 
platelet count; the presence or absence of ascites; BRCA status; and various molecular 
markers.4-6 In recent years there has been an increasing interest in the prognostic value of 
human epididymis-protein 4 (HE4), a new molecular biomarker that is overexpressed mainly 
in serous and endometrioid epithelial ovarian cancer.7 This epithelial protein has already been 
shown to be an independent prognostic factor for reduced OS and progressive disease in other 
malignancies such as endometrial, lung and breast cancer.8-10  
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However, the prognostic value of serum HE4 for these clinical outcomes in patients with 
ovarian cancer has yet to be fully explored. Inconsistent data exist in the literature based only 
on studies limited to patients with epithelial ovarian cancer scheduled for primary debulking 
surgery (PDS) with adjuvant chemotherapy.11-18  
Following the identification of serum HE4, most clinical research has focused on its 
usefulness for the diagnosis of ovarian cancer and more specifically for risk stratification in 
combination with serum CA 125 as the Risk of Ovarian Malignancy Algorithm (ROMA) in 
women presenting with a pelvic mass.19 Although this risk index has been optimized for use 
as a diagnostic tool, high ROMA scores have also been reported to be independently 
associated with an unfavorable prognosis in a selected group of patients with ovarian cancer.14 
In this study we aimed to further investigate the independent prognostic importance of 
pretreatment serum HE4 levels and ROMA scores at time of the initial diagnosis of ovarian 
cancer with respect to PFS and disease-specific survival (DSS) in a population of patients 
with ovarian cancer receiving either PDS or neo-adjuvant chemotherapy (NACT) with 
interval debulking surgery.  
 
Materials and Methods  
Study cohort: In this retrospective time-to-event analysis we included all consecutive newly 
diagnosed cases (n=101), of biopsy proven, FIGO stage I-IV invasive ovarian cancer that 
received either PDS or NACT from a previous diagnostic accuracy study (ProDoC) conducted 
at the University Hospital KU Leuven, Belgium. This study had been approved by the Ethics 
Committee of the University Hospital KU Leuven (reference: OG032/ML3132). The 
methodology for this study has been described in detail elsewhere.20 All included patients 
gave written informed consent before plasma and tissue samples were collected. For this 
study, data (n=389) was collected prospectively from August 2005 to March 2009. It enrolled 
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a total of 161 malignant (31 borderline ovarian tumors, 102 invasive ovarian cancers, 2 
uterine sarcomas and 26 metastatic tumors to the ovary) and 228 benign tumors. We excluded 
one case of invasive ovarian cancer from our survival analysis as this patient did not receive 
any form of medical treatment. 
The final study cohort (n=101) comprised 80 patients (79%) who underwent PDS by 
gynecologic oncologists with maximal effort to resect all tumor tissue present. The majority 
of these patients (92%) received an adjuvant first-line platinum-based chemotherapy regimen 
after PDS. In total five patients with stage I, well-differentiated invasive cancers did not 
receive adjuvant treatment.  
Neo-adjuvant platinum-based chemotherapy was initiated in 21 patients (21%) all with bulky 
FIGO stage IIIC-IV disease. Histology (tumor type, grade) was derived before initiation of 
NACT either by imaging-guided biopsies (n=1), during prior diagnostic laparoscopy to assess 
primary resectability of the disease (n=19) or explorative laparotomy (n=1). Interval 
debulking surgery was performed in only 14 out of 21 patients (67%) after hematological 
recovery, but within 6 weeks of completion of the third chemotherapy cycle. The first cycle of 
chemotherapy after surgery was administered as soon as possible, but no more than six weeks 
later.  
Assessment of progression-free and disease-specific survival: Follow-up visits (physical 
examination and serum CA125) were scheduled every three months during the first two years 
following completion of chemotherapy, then semiannually for three years and yearly 
thereafter. Imaging (i.e. computed tomography (CT) abdomen (and if applicable CT thorax)) 
was used whenever there was a clinical suspicion of disease progression and assessed 
according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria.21,22  
Progression free survival was measured from start of primary therapy (i.e. date of PDS or first 
NACT) until the documented date of first relapse, death from any cause, or the date of last 
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contact (until 31 December 2012) in hospital record files for patients that were still alive and 
progression-free.  
Disease specific survival was defined as the time interval between the start of treatment and 
the date of death related to ovarian cancer as documented in the hospital record files. 
Competing risk events (i.e. death from other causes) not directly related to ovarian cancer 
were censored. The last date of documented follow-up up until 31 December 2012 was used 
to censor surviving patients (both progression-free and relapsed patients).  
Most treated patients (either progression-free or relapsed) attained careful follow-up in our 
center. For some patients completeness of survival data was ensured by clinical trial nurses 
who contacted general practitioners or treating oncologists in other hospitals every three to 
four months. 
Serum samples, biomarker assays, and ROMA: Blood samples were obtained prior to first-
line standard therapy (PDS or NACT) and collected in 10 ml clotting activating tubes (BD 
Vacutainer Serum Tube, ref. 369033; Becton-Dickinson, Erembodegem, Belgium). Serum 
tubes were centrifuged at 800 g for 10 min. Serum was collected, dispensed into multiple 
cryotubes and frozen at −80 °C. Serum CA125 concentrations were measured using the 
CanAg CA 125 EIA assay (Fujirebio Diagnostics, Göteborg, Sweden) and serum HE4 
concentrations were measured using the HE4 EIA assay (Fujirebio Diagnostics). Both assays 
are solid-phase, non-competitive immunoassays, based on the direct sandwich technique, and 
were run according to manufacturer's instructions. Each ELISA was performed manually and 
in duplicate for calibrators, controls and patient samples. The appropriate controls were within 
the ranges provided by the manufacturer for all runs.  
The ROMA algorithm classifies patients as being at a low or at a high risk for malignant 
disease using the following algorithms and thresholds according to the manufacturer’s insert: 
 7
for premenopausal women the linear predictor z equals −12.0 + (2.38 × LN(HE4)) + (0.0626 
× LN(CA125)); for postmenopausal women z equals −8.09 + (1.04 × LN(HE4)) + [0.732 × 
LN(CA125)). The probability of malignancy equals 1/ (1 + exp (-z)). 
Statistical analysis: Statistical analysis was conducted according to the reporting 
recommendations for tumor marker prognostic studies (REMARK)23 and performed with R 
version 2.15 (www.r-project.org) and Medcalc, version 12.3.0.0, (MedCalc Software, 
Mariakerke, Belgium). To analyse the association of serum HE4 and ROMA scores with 
other prognostic variables we used the difference between medians with its 95% confidence 
interval (CI) (Bonett & Price, Psychological Methods 2002). For descriptive purposes, median 
values of serum HE4 and ROMA were used to indicate low– and high-risk groups. For 
descriptive purposes, overall and risk-group-stratified survival rates were estimated with the 
Kaplan–Meier method.  
Time-to-event analysis was performed using classical Cox proportional hazards regression. 
First, univariable models were examined using either HE4 or ROMA scores as predictor of 
survival. Then, we fitted multivariable models containing classical prognostic variables, 
treatment type, as well as either serum HE4 or ROMA scores. In all Cox models, HE4 and the 
ROMA score were included as continuous variables and thus were not dichotomized. As co-
variables we considered age (continuous), FIGO stage (stage III-IV versus stage I-II), tumor 
grade (2-3-high grade not-other-specified (NOS) versus 1), histology (serous versus non-
serous), residual tumor load after surgery24 (residual disease versus no macroscopic disease), 
presence of ascites (yes versus no), World Health Organization (WHO) performance status 
(categorical, I to III) and treatment type (NACT versus PDS). Main interest was in the crude 
(univariable) and adjusted (multivariable) hazard ratios (HR) for serum HE4 and the ROMA 
score. The proportional hazards assumption for the predictors was verified using Scaled 
Schoenfeld residuals. Only serum HE4 did not fulfill the linearity assumption, which was 
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checked by means of the Martingale residuals. After log-transformation, this assumption was 
fulfilled.  
To account for the small number of events (i.e. death, progression) we also computed 
penalized hazard ratios (HR) that were based on a multivariable Cox model using a ridge 
penalty. This method avoids overoptimistic effects of the predictor variables. The penalization 
parameter lambda was derived using 10-fold cross-validation. This analysis was done in R 
(www.r-project.org) using the glmnet package.25   
Results 
The clinico-pathological features of the 101 patients with invasive ovarian cancer are 
summarized in Table 1. Most patients (74%) presented with stage III-IV disease and had 
serous ovarian cancer (67%). A complete debulking to no macroscopic residual tumor was 
achieved in 86% of patients that received PDS or interval debulking surgery. In patients 
treated with PDS (73/80) 91% were debulked to no residual disease. In patients that were 
debulked after NACT (8/14) 57% were debulked to no residual disease. Those patients that 
could not receive interval debulking surgery (7/21) after 3 cycles of NACT were all classified 
as having residual tumor burden. Patients receiving NACT and interval debulking surgery 
were more likely to be older, have a lower WHO performance status, higher FIGO stage, and 
serous type cancer. Median levels (interquartile range) of pretreatment serum HE4 and 
ROMA were 274 (pM) (96-699), and 90% (58-98), respectively.  
We observed higher pretreatment HE4 levels and higher ROMA scores, in patients with 
advanced FIGO stage, with grade 2-3 or high grade NOS tumors, serous histology, ascites and 
residual tumor load after primary treatment (Table 2).   
The median overall survival time was 3.7 years (95% CI: 3.2-4.1) for the entire study cohort. 
Fifty-two patients (52%) died of their disease during follow-up. One additional patient died of 
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a bowel perforation with peritonitis unrelated to ovarian cancer and this case was censored. 
Median follow-up time until first progression was 1.7 years 95%CI (1.3-1.9). Seventy-four 
(74%) cases had progressive disease after primary therapy.  
Univariable analysis suggested that higher serum HE4 levels and ROMA scores were 
associated with worse prognosis for PFS and DSS (Figure 1). Table 3 and 4 represent the 
full multivariable Cox model for PFS and DSS with adjusted HRs for each  predictor variable. 
After controlling for known prognostic variables and treatment type no independent 
associations of pretreatment serum HE4 (adjusted HR for each doubling in HE4 level = 0.98, 
95% CI 0.84 to 1.13) or of ROMA scores (adjusted HR for each 10% increase in risk = 0.98, 
95% CI 0.88 to 1.11) with PFS were suggested. Similar results were obtained for DSS; the 
adjusted HR for each doubling in the HE4 level was 1.01 (0.84 to 1.21), the adjusted HR for 
each 10% increase in ROMA score was 0.96 (0.84 to 1.12). Penalized Cox regression reduced 
the effect size (HR) to PFS and DSS for most predictor variables.  
Discussion 
This study investigated the prognostic value of serum HE4 and ROMA scores at the time of 
initial diagnosis in patients with invasive ovarian cancer treated with either PDS or NACT. 
On univariable analysis our data suggested that patients with elevated levels of serum HE4 or 
ROMA scores had an unfavorable PFS or DSS. However, this association is very likely to be 
explained by other prognostic variables since the effect sizes disappeared after multivariable 
adjustment for classical prognostic variables.    
The strengths of this study include the use of prospectively collected data from a previous 
diagnostic accuracy study; adequate steps taken to ensure completeness of survival data; and 
the inclusion of patients with ovarian cancer that received either PDS or NACT to support the 
generalizability of our findings and minimize selection bias. Moreover, NACT followed by 
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interval debulking is clinically used as a valuable alternative for patients with advanced stage, 
bulky disease as it is not inferior to PDS followed by adjuvant chemotherapy.26 Previous 
studies reporting on the prognostic value of serum HE4 in patients with epithelial ovarian 
cancer were limited to those treated with PDS.11-18 Patients that received NACT followed by 
interval debulking were all excluded from further analysis as it was suggested that this type of 
treatment might affect the assessment of FIGO staging, tumor type and tumor grading.13 Since 
most patients that received NACT in our study underwent a prior diagnostic laparoscopy to 
evaluate disease extent and to obtain histology, we believe we have minimized the risk of 
introducing bias.  
There are some limitations to address to this study. The small number of events in this study 
limits the number of predictor variables that can be entered in the Cox model. In addition thel 
use of penalized Cox regression aims to avoid overoptimistic effect sizes (hazard ratios). As 
shown this led to a reduction in the effect size for most variables. Another possible limitation 
to this study could be that we decided to report the prognostic significance of serum HE4 in 
relation to PFS and DSS, whereas other studies also explored the predictive value of a 
prognostic risk index composed of serum HE4 and CA 125 using receiver-operating 
characteristics (ROC) curve analysis for secondary outcomes like platinum resistance and 
residual tumour burden.11, 12 This risk index combining CA125 (cut off value 500 IU/ml) and 
HE4 (cut off value 500 pM) was an independent predictive factor for surgical outcome in a 
multivariable setting (OR = 6.041, 95% CI 2.33 to 15.65).11 Another study has showed an 
improved positive predictive value (PPV) in relation to platinum resistance for the 
combination of markers (cut-off upper third centile for both CA 125 and HE4) than for each 
marker individually.12  
Instead, we evaluated the combination of both markers in the context of the diagnostic 
ROMA algorithm. It is important to emphasize that this risk score has been developed and 
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optimized only to differentiate between the benign or malignant nature of an adnexal mass 
and not for predicting disease outcome where its utility has only been explored in one study.14 
In contrast to our findings, in this study elevated ROMA scores were independently 
associated with impaired PFS (2.76; 1.15-6.59) and OS (3.22; 1.21-8.57).14 However, this 
recruitment was limited to patients with epithelial ovarian cancer treated with PDS, the study 
had a short median follow-up time (19 months), excluded almost 10% of patients from 
survival analysis due to incomplete follow-up, and did not use RECIST criteria to define 
progressive disease.14  
Our findings with respect to the prognostic relevance of pretreatment serum HE4 were in line 
with a large study conducted by the OVCAD consortium.11 This study with a median follow-
up time of 25 months (range 1–49 months), in which 83 patients (30%) died during follow-up 
and 182 patients developed a recurrence, also found that serum HE4 was not an independent 
prognostic factor for PFS and OS. However, in contrast to our design, they excluded early 
stage disease due to its excellent prognosis and used serum HE4 as a categorical variable in 
their multivariable survival analysis.11  
Most initial reported results of prognostic studies dealing with serum HE4 showed great 
promise.12-18 High levels of serum HE4 proved to be strong and independent indicators of a 
worse prognosis in patients with epithelial ovarian cancer, or only in those with advanced 
disease.17 Our results contradict these reports. Whilst on univariable analysis both HE4 and 
ROMA were related to unfavorable prognosis, multivariable analysis shows they were not 
independent predictors.  
A variety of problems are likely to explain discrepancies in outcomes of prognostic research, 
such as general methodological differences, poor study design, assays that are not 
standardized or lack reproducibility, and inappropriate or misleading statistical analyses.27 
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There are clear differences between studies exploring the prognostic value of serum HE4 
including sample size, the median length of follow-up, the total number of events, and the 
type of prognostic variables entered in multivariable survival analysis. In addition, most 
studies selected patients with epithelial ovarian cancer11-18, one study focused only on serous 
type cancer12, and many did not use CA 125 or RECIST criteria21, 22 to define progressive 
disease or were unclear about how to define this clinical outcome.14,15,17 Furthermore, two 
studies did not use serum HE4 levels at time of diagnosis, but in contrast analyzed samples 
taken after PDS.12,16 To overcome this considerable heterogeneity, it is essential that 
methodology for prognostic studies on serum HE4 should be more harmonized as this will 
only facilitate future data-synthesis in systematic reviews. 
To conclude, whereas biomarkers such as serum HE4 or biomarker algorithms like ROMA 
are attractive tools in ovarian cancer diagnostics, this study provides evidence of their limited 
ability to indicate risk groups for worse overall prognosis in patients with ovarian cancer 
treated either by primary surgery or neo-adjuvant chemotherapy, when taking classical 
clinico-pathological factors into account. 
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Table 1. Clinico-pathological characteristics in patients (n=101) with invasive ovarian cancer.  
Characteristic Result 
Age (years), median (IQR) 60 (52 – 67) 
FIGO stage  
I 20 (19.8%) 
II 6 (5.9%) 
III 61 (60.4%) 
IV 14 (13.9%) 
Malignant Histology  
Serous 68 (67.3%) 
Mucinous 7 (6.9%) 
Clear cell 6 (5.9%) 
Carcinosarcoma 4 (4.0%) 
Endometroid 7 (6.9%) 
Mixed 5 (5.0%) 
Undifferentiated 2 (2.0%) 
Sex cord stromal tumor 2 (2.0%) 
Tumor grade differentiation  
1 13 (12.9%) 
2 14 (13.9%) 
3 71(70.3%) 
High grade NOS 3 (2.9%) 
Ascites  
Yes 52 (51.5%) 
No 49 (48.5%) 
WHO  
0 42 (41.6%) 
1 54 (53.5%) 
2 5 (4.9%) 
Residual tumor load  
Yes 21 (20.8%) 
No 80 (79.2%) 
Preoperative biomarker and ROMA levels   
Serum CA125 (IU/mL), median (IQR)  541 (104-1381) 
HE4 (pM), median (IQR) 274 (96-699) 
ROMA score (%),median (IQR) 90  (58-98) 
 
Abbreviations: NOS: not other specified; IR: interquartile range; ROMA: risk of ovarian malignancy 
algorithm, FIGO: International Federation of Obstetrics and Gynecology. 
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Table 2. Median levels of serum HE4 and ROMA scores according to standard prognostic factors in 
women with invasive ovarian cancer.  
  HE4 (pM) ROMA (%) 
Prognostic 
factor 
N Median Difference 
(95% CI) 
Median Difference 
(95% CI) 
FIGO stage 
I-II 26 87.8 339  
(169; 509) 
48.2 47  
(22; 71) III-IV 75 426.8 94.9 
Histology 
Non-serous 33 102.1 342  
(160; 524) 
60.0 35  
(12; 95) Serous 68 443.9 95.5 
Tumor grade 
(1) 13 119.9 163  
(-71; 397) 
74.5 17  
(-17; 50) (2-3-high grade 
NOS) 
88 282.9 91.1 
Residual tumor load after primary treatment 
No 81 217.5 359  
(154; 565) 
86.2 11  
(1; 22) Yes 20 576.9 97.4 
Presence of ascites 
No 49 138.2 365  
(163; 567) 
67.8 27  
(8; 46) Yes 52 503.6 94.9 
 
Abbreviations: ROMA: risk of ovarian malignancy algorithm, FIGO: International Federation of 
Obstetrics and Gynecology, NOS: not other specified. 
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Table 3. Expanded Cox Model for Progression Free Survival (PFS) and Disease-specific survival ( 
DSS) including classical prognostic variables, treatment type and serum HE4. 
 PFS DSS 
Prognostic 
variable HR 95% CI 
Penalized 
HR HR 95% CI 
Penalized 
HR 
HE4, per doubling 0.98 0.84-1.13 1.02 1.01 0.84-1.21 1.02 
Age, per 10 years 0.92 0.72-1.17 0.98 1.16 0.86-1.58 1.13 
WHO score 1 vs 0 1.13 0.66-1.96 1.08 1.01 0.51-2.03 1.00 
WHO score 2 vs 0 4.11 1.22-11.9 2.95 7.43 2.02-23.8 4.97 
Serous vs non-
serous 
1.19 0.59-2.55 1.27 0.63 0.28-1.50 0.79 
Differentiation 
grade 2/3/high 
grade NOS vs 1 
5.42 1.91-22.8 2.67 5.74 1.62-36.7 2.60 
FIGO stage III/IV 
vs I/II 
3.50 1.34-10.5 2.09 2.06 0.66-7.99 1.74 
Residual tumor 
load (yes vs no) 
3.09 1.41-6.87 2.29 5.76 2.52-13.6 3.71 
Treatment (NACT 
vs PDS) 
1.58 0.68-3.53 1.51 1.40 0.58-3.28 1.46 
Presence of 
ascites 
1.60 0.96-2.76 1.49 2.73 1.41-5.60 1.92 
HE4 was log2-transformed such that the effect can be expressed per doubling of the marker level. 
Penalized results were based on a multivariable Cox model using a ridge penalty, where the 
penalization parameter lambda was derived using 10-fold cross-validation. 
Abbreviations: FIGO: International Federation of Obstetrics and Gynecology, WHO: world health 
organization, NOS: not other specified, NACT: neo-adjuvant chemotherapy, PDS: primary debulking 
surgery, DSS: disease specific survival, PFS: progression free survival, HR: hazard ratio . 
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Table 4. Expanded Cox Model for Progression Free Survival (PFS) and Disease-specific survival (DSS) 
including prognostic variables, treatment type and ROMA. 
 PFS DSS 
Prognostic 
variable HR 95% CI 
Penalized 
HR HR 95% CI 
Penalized 
HR 
ROMA risk, per 
10% 
0.98 0.88-1.11 1.01 0.96 0.84-1.12 1.00 
Age, per 10 years 0.92 0.73-1.17 0.97 1.16 0.86-1.58 1.13 
WHO score 1 vs 0 1.11 0.65-1.92 1.09 1.00 0.51-2.01 1.01 
WHO score 2 vs 0 4.04 1.20-11.6 3.17 7.47 2.02-24.1 5.14 
Serous vs non-
serous 
1.19 0.59-2.55 1.25 0.68 0.29-1.64 0.79 
Differentiation 
grade 2/3/high 
grade NOS vs 1 
5.28 1.88-22.1 2.96 5.79 1.64-37.0 2.71 
FIGO stage III/IV 
vs I/II 
3.54 1.31-10.8 2.21 2.31 0.71-9.23 1.80 
Residual tumor 
load (yes vs no) 
3.14 1.43-6.99 2.40 5.89 2.57-14.0 3.81 
Treatment (NACT 
vs PDS) 
1.56 0.68-3.47 1.52 1.45 0.60-3.41 1.47 
Presence of 
ascites 
1.63 0.96-2.84 1.50 2.76 1.43-5.63 1.96 
Penalized results were based on a multivariable Cox model using a ridge penalty, where the 
penalization parameter lambda was derived using 10-fold cross-validation. 
Abbreviations: ROMA: risk of ovarian malignancy algorithm, FIGO: International Federation of 
Obstetrics and Gynecology, WHO: world health organization, NOS: not other specified, NACT: neo-
adjuvant chemotherapy, PDS: primary debulking surgery, DSS: disease specific survival, PFS: 
progression free survival, HR: hazard ratio . 
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Figure 1.  
Kaplan-Meier curves showing Progression Free Survival (PFS) and Disease Specific 
Survival (DSS) stratified for serum HE4 and Risk of Ovarian Malignancy Algorithm 
(ROMA) scores  using a median split. 
Time in years 
 
 
 
